Summit Therapeutics Inc. (SMMT) Free cash flow 2018–2025
Summit Therapeutics Inc. (SMMT) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$323.6MFY2025 · since FY2018: -$22.2M → -$323.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$323.6M | -127.5% |
| FY2024 | -$142.2M | -85.0% |
| FY2023 | -$76.9M | -82.2% |
| FY2022 | -$42.2M | +42.1% |
| FY2021 | -$72.9M | -50.2% |
| FY2020 | -$48.5M | -37.6% |
| FY2019 | -$35.3M | -59.1% |
| FY2018 | -$22.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice